Payment overview · 2025
General Payments
$1,345.87
79 reported records · 19 companies
Healthcare provider profile · identity verified
Ryan David Simonak, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FORT WORTH, TX · NPI 1871721993
Verified facts
What the public records show
CMS Open Payments records show Ryan David Simonak, D.O. received $1,345.87 in general payments during 2025 across 79 reported records.
ABBVIE INC. accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $244.17 | 18.1% | 17 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $201.75 | 15.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $145.75 | 10.8% | 9 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $142.67 | 10.6% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.65 | 7.8% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.53 | 5.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.21 | 4.5% | 4 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $56.58 | 4.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.53 | 3.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.73 | 3.8% | 3 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $34.33 | 2.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.72 | 2.4% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.43 | 2.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.34 | 1.8% | 1 | 2025 |
| Endo USA, Inc. | Unresolved — no canonical attribution shown | $24.25 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.15 | 1.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.22 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.53 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.33 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,345.87 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $201.75 | 9 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $142.67 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $134.17 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $133.11 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $110.00 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $108.79 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.17 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $74.53 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $56.58 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $51.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.59 | 3 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| AVEED Normalized: aveed |
Biological | Endo USA, Inc. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $12.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $12.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $12.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 83 |
| Metformin Hcl Er | Metformin Hcl | 241 | 78 |
| Losartan Potassium | Losartan Potassium | 192 | 63 |
| Lisinopril | Lisinopril | 188 | 66 |
| Montelukast Sodium | Montelukast Sodium | 160 | 61 |
| Liothyronine Sodium | Liothyronine Sodium | 143 | 41 |
| Omeprazole | Omeprazole | 139 | 55 |
| Meloxicam | Meloxicam | 133 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 43 |
| Trazodone Hcl | Trazodone Hcl | 112 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 41 |
| Metformin Hcl | Metformin Hcl | 110 | 40 |
| Furosemide | Furosemide | 107 | 44 |
| Ozempic | Semaglutide | 106 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 34 |
| Prednisone | Prednisone | 92 | 59 |
| Allopurinol | Allopurinol | 91 | 33 |
| Gabapentin | Gabapentin | 82 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 30 |
| Ibandronate Sodium | Ibandronate Sodium | 76 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 31 |
| Jardiance | Empagliflozin | 68 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 52 |
| Propranolol Hcl Er | Propranolol Hcl | 66 | 18 |
| Celecoxib | Celecoxib | 64 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 32 |
| Carvedilol | Carvedilol | 62 | 20 |
| Simvastatin | Simvastatin | 62 | 21 |
| Eliquis | Apixaban | 58 | 14 |
| Mounjaro | Tirzepatide | 58 | 16 |
| Potassium Chloride | Potassium Chloride | 56 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 22 |
| Atenolol | Atenolol | 53 | 17 |
| Tramadol Hcl | Tramadol Hcl | 51 | 28 |
| Cefdinir | Cefdinir | 50 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 20 |
| Methocarbamol | Methocarbamol | 41 | 32 |
| Famotidine | Famotidine | 40 | 15 |
| Finasteride | Finasteride | 40 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 19 |
| Anastrozole | Anastrozole | 39 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 15 |
| Sertraline Hcl | Sertraline Hcl | 36 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 15 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 20 |
| Estradiol | Estradiol | 29 | 12 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Np Thyroid | Thyroid,pork | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 11 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | 11 |
| Progesterone | Progesterone, Micronized | 19 | 11 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,345.87 · 79 records | ABBVIE INC. | ABRYSVO, AVEED, AZMIRO, CAPLYTA, COMIRNATY, CYCLOSET, Dexcom G6 Transmitter, Dyanavel XR, FREESTYLE LIBRE, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, UNITHROID, VRAYLAR, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error